SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas strong Q3 results and raised outlook, including an aggressive 2027 growth forecast, are driving attention amid demand for AI data-center infrastructure. Many traders are bullish on the outlook but puzzled by the volatile share-price reaction, while others question cash-flow trends and whether AI spending can sustain the growth.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention as its shares sell off amid crypto risk-off, with traders arguing it is falling harder than Ethereum and questioning its discount to net asset value and Tom Lees strategy. Bulls point to continued ETH accumulation and buybacks, while skeptics doubt those actions will close the valuation gap or sustain interest as the treasury buildout nears its target.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals quarterly report is the main focus, with traders weighing bearish options positioning and concerns about branded-checkout growth and margins against hopes for a strong report and improved guidance. Takeover and bank-charter speculation also appears, but neither is confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is drawing attention after a disappointing third-quarter report and a sharp reduction in its 2026 earnings outlook, with weak appliance demand and higher costs weighing on sentiment. Traders are divided between buying the steep selloff as a value opportunity and warning that heavy debt and worsening results could deepen the downturn.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XP is plunging amid a broad selloff in Brazilian assets after Lula da Silvas election victory, as traders cite uncertainty over government spending and fiscal discipline. Many see the drop as an election-driven overreaction and look for a rebound, while others warn that the volatility and selling may continue.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazilian equities plunged after Lulas unexpected runoff victory, as concerns about government spending and fiscal discipline drove a broad repricing. Traders are divided between viewing the selloff as a sign of prolonged political and economic risk and treating it as an overreaction or dip-buying opportunity.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Reports that DoorDash is in advanced talks to acquire Instacart are driving attention and the sharp move. Traders are weighing buyout optimism against doubts about the valuation and whether a deal will actually get done.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credos sharp swings have centered on concern that MaxLinear plans to challenge its position in active electrical cables, alongside broader weakness in AI-related stocks. Traders are divided between selling on competitive and market risks and buying the pullback on expectations that AI data-center connectivity demand will continue to support growth.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

Reports that DoorDash is in advanced talks to acquire Instacart are driving attention, with traders debating whether the deal would strengthen its grocery-delivery network or be an expensive, antitrust-risky purchase. The talks are not a finalized deal, and the news is coinciding with a sharp decline in DASH shares.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is drawing attention after Q3 results fell short of expectations and its Q4 outlook came in below consensus, renewing pressure on the stock. Traders are split between viewing the report as a further sign of weak near-term performance and arguing the negative news is priced in, with long-term optimism around AI-related advanced-packaging demand and customer partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.read more...

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results

Equity

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.read more...

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline...

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...

Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...

Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Dianthus Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Following the update, investment bank Raymond James reaffirmed its ‘Strong Buy’ rating on Dianthus and kept its price target at $125 per share.</li><li>The analyst said the 75% response rate exceeded expectations and compared favorably with Sanofi’s competing drug.</li><li>Sanofi discontinued its late-stage study of riliprubart in patients with CIDP who had failed or responded inadequately to standard treatments earlier this month.</li></ul>Shares of Dianthus Therapeutics, Inc. (DNTH) jumped 8% on Friday after the company reported positive early data from its ongoing late-stage trial of claseprubart, an experimental drug for chronic inflammatory demyelinating polyneuropathy (CIDP).The DNTH stock, on Friday, clocked its best session since early March.CIDP is a rare nerve disorder that causes weakness, numbness and loss of function in the arms and legs. It occurs when the immune system mistakenly attacks the nerves. Current treatments often involve frequent infusions or steroids.<h2 class="st-heading-2">What Dianthus’s Study Showed</h2>In the first part of the study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said. The company was expecting 50%, and the results clearly exceeded its own targets.The trial has a two-part design. In the initial part, patients received claseprubart. Those who improved were then moved into the next part of the study, where some continued on the drug, and others switched to a placebo. The goal is to see how long it takes for symptoms to return when the drug is stopped.The high response rate in the first part was seen across several measures of how well patients could move and function, the company said. Claseprubart is given as an under-the-skin injection every two weeks using a pre-filled pen, which could make it more convenient than current CIDP treatments like IVIG infusions.Dianthus also said on Friday that it now expects to provide guidance on the timing of the Part B top-line results by the end of 2026.<h2 class="st-heading-2">Analyst Reaction</h2>Following the update, investment bank Raymond James reaffirmed its ‘Strong Buy’ rating on Dianthus and kept its price target at $125 per share. The analyst noted that the 75% response rate beat their expectations and stood out favorably compared to Sanofi’s competing drug. They also highlighted that the study’s design — starting with open treatment and then testing what happens when the drug is withdrawn — appears to be a lower-risk approach than the one used in Sanofi’s failed study.Sanofi discontinued its late-stage study of riliprubart in patients with CIDP who had failed or responded inadequately to standard treatments earlier this month. The company announced that an independent data monitoring committee had reviewed interim data and concluded the study was unlikely to meet its efficacy goals. The decision came after riliprubart had shown more modest results in an earlier mid-stage study, where roughly 50% of refractory patients improved at week 24. Sanofi is now evaluating whether to continue its other ongoing late-stage trial in patients already on maintenance IVIg.Dianthus, meanwhile, is also studying claseprubart in generalized myasthenia gravis and multifocal motor neuropathy as well.<h2 class="st-heading-2">How Did DNTH Retail Traders React?</h2>On Stocktwits, retail sentiment around DNTH stock fell from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume remained at ‘extremely high’ levels.According to data from Koyfin, all 15 analysts covering DNTH rate it a ‘Buy.’ The stock has a 12-month average price target of $127.67, implying a potential upside of about 56% from Friday’s close.<a href="https://stocktwits.com/symbol/DNTH">DNTH stock</a> has more than doubled this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hood-stock-robinhood-buckles-under-spacex-ipo-demand/cZKdI35R75Q">HOOD Stock: Robinhood Buckles Under SpaceX IPO Demand, Users Report Trading Issues</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Dianthus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sanofi-Aventis

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$79.33
Prev Close	$76.78
Open	$77.87
Dividend Yield	0.00%
50-Day Moving Average	$96.03
Beta	1.13
Avg. Volume	877,133.03
PE Ratio	-18.49

52-Week High	$117.88
52-Week Low	$32.28
Market Capitalization	$4.29B
EPS (Annual)	-$4.20
Price to Book	3.59
Revenue Per Employee	$22,130.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNTH Fundamentals